Observational studyBMC nephrology2026
Features and management of kidney manifestations of tuberous sclerosis complex: a real-world study in a Brazilian patient cohort.
Observational study in BMC nephrology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTuberous sclerosis complex (TSC) is a rare autosomal dominant disorder resulting from pathogenic variants in the TSC1 or TSC2 genes, leading to hyperactivation of the mechanistic target of rapamycin (mTOR) pathway and subsequent development of benign neoplasms in multiple organs. Kidney involvement is frequent, being angiomyolipoma the most common lesion. Angiomyolipoma can occur since childhood and progress throughout life, potentially leading to complications such as hemorrhage and chronic kidney disease (CKD). This study aims to characterize the kidney phenotype in a Brazilian cohort of TSC patients and identify potential risk factors associated with kidney complications.
methodsThis real-world retrospective observational study analyzed data from TSC patients recorded on their first nephrology consultation at two Brazilian university hospitals between September 2019 and August 2024. Clinical, laboratory and imaging data were collected from medical records. Comparative analyses were conducted based on sex, history of kidney hemorrhage, kidney invasive interventions and CKD G3-G5D.
results172 patients were included (28 ± 14.2 years, 62.2% female, 22.7% pediatric). Angiomyolipoma was the most frequent renal lesion (91.7%) with increasing prevalence with age, followed by cysts (45.2%). 41.9% of the patients meeting renal indications were receiving mTOR inhibitor. The prevalence of CKD G3-G5, kidney hemorrhage and interventions was 9.9%, 16.6%, and 27.9%, respectively. Comparative analysis matched by age showed that female patients have slightly lower eGFR (117 [94-127] vs. 126 [97-149] mL/min/1.73m
conclusionsThis Brazilian cohort study demonstrated that TSC-related kidney involvement may occur early in life, displays a progressive profile and leads to severe kidney outcomes. The high rates of kidney complications and the suboptimal utilization of mTOR inhibitors underscore the need to increase awareness, early referral to nephrologist and timely therapeutic intervention.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.